Maad Rayan Publishing Company Biomedical Research Bulletin 2980-9924 2 4 2024 12 29 Insights on Benzodiazepine’s Contribution to Neuroinflammation and Alzheimer’s Disease Biomarkers 199 203 10.34172/biomedrb.2024.27 EN Maryam Azarfarin https://orcid.org/0009-0002-2815-459X Masoomeh Dadkhah https://orcid.org/0000-0003-0274-1075 Sara Salatin https://orcid.org/0000-0001-9107-5603 REVIEW 10.34172/biomedrb.2024.27 2024 11 01 2024 12 17 Benzodiazepines (BZDs) are a class of prescription medications widely used for their anxiolytic, hypnotic, and muscle relaxant properties. Prolonged use of BZDs has been shown to increase the risk of abuse, dependence, and relapse in patients. Elderly people are particularly more vulnerable to the effects of BZDs due to altered pharmacokinetics and pharmacodynamics, along with drug interactions resulting from polypharmacy. These processes initiated by BZDs may trigger the onset of cognitive pathologies such as Alzheimer’s disease (AD). The present study focused on the relationship between BZD use and its contribution to neuroinflammation in AD. Moreover, it summarized some studies evaluating the effect of BZDs in the AD population.